Full Coverage

Medicines Co. Shares Fall after FDA Rejects Angiomax

ibtimes.com
May 28, 2008
        
Story Timeline:  190 days

The Medicines Company said on a press release on Wednesday that it received a not approvable letter from U.S. regulators on a supplemental New Drug Application for an additional dosing regimen for Angiomax in the treatment of acute coronary syndromes. [read full story]                    

Add Comment
Latest article on this story:

The Medicines Company Receives FDA Review Letter For Angiomax Supplemental Filing

 medicalnewstoday.com May 30, 2008
First article on this story:

The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing

 finanznachrichten.de May 28, 2008
Selected publications with coverage of this story:
ibtimes.com medicalnewstoday.com euroinvestor.co.uk pharmiweb.co.uk m2.com finanznachrichten.de
RELATED
Found 3 documents:
                   

The Medicines Company Receives FDA Review Letter For Angiomax Supplemental Filing

medicalnewstoday.com
May 30, 2008
        

The Medicines Company (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S. Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax®...

The Medicines Company announces receipt of FDA review letter for Angiomax supplemental filing

m2.com
May 29, 2008
        

The Medicines Company (NASDAQ:MDCO), which is focused on advancing the treatment of critical care patients through the delivery of cost-effective medicines to the hospital marketplace, said on 28 May that the company has received a non approvable letter f

                   

The Medicines Company Receives FDA Review Letter for Angiomax Supplemental Filing

finanznachrichten.de
May 28, 2008
        

The Medicines Company (NASDAQ: MDCO) announced receipt of a not approvable letter from the U.S. Food and Drug Administration (FDA) on a supplemental New Drug Application (sNDA) for an additional dosing regimen for Angiomax® (bivalirudin) in the treatment of acute coronary syndromes (ACS)...